Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in ACXP held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 31K | $48K | 0.0% | 0.724% | 0.00% |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 26K | $41K | +6.4% | 0.615% | 0.00% |
| 3 | VANGUARD FIDUCIARY TRUST CO | 16K | $25K | 0.0% | 0.377% | 0.00% |
| 4 | JANE STREET GROUP, LLC | 16K | $24K | -71.2% | 0.366% | 0.00% |
| 5 | Prospect Financial Services LLC | 14K | $21K | 0.0% | 0.321% | 0.01% |
| 6 | MORGAN STANLEY | 8K | $12K | +15.4% | 0.174% | 0.00% |
| 7 | Tower Research Capital LLC (TRC) | 3K | $4K | +166.2% | 0.064% | 0.00% |
| 8 | WELLS FARGO & COMPANY/MN | 2K | $4K | 0.0% | 0.053% | 0.00% |
| 9 | Westside Investment Management, Inc. | 2K | $3K | 0.0% | 0.038% | 0.00% |
| 10 | LANARK FINANCIAL, INC. | 2K | $2K | 0.0% | 0.035% | 0.00% |
| 11 | BARCLAYS PLC | 281 | $436 | -26.1% | 0.006% | 0.00% |
| 12 | Cornerstone Planning Group LLC | 167 | $245 | 0.0% | 0.004% | 0.00% |
| 13 | OSAIC HOLDINGS, INC. | 100 | $155 | 0.0% | 0.002% | 0.00% |
| 14 | GROUP ONE TRADING LLC | 95 | $147 | -61.2% | 0.002% | 0.00% |
| 15 | BlackRock, Inc. | 60 | $93 | 0.0% | 0.001% | 0.00% |
| 16 | Caitong International Asset Management Co., Ltd | 23 | $36 | — | 0.001% | 0.00% |
| 17 | SBI Securities Co., Ltd. | 6 | $9 | 0.0% | 0.000% | 0.00% |
| 18 | UBS Group AG | 3 | $5 | -100.0% | 0.000% | 0.00% |
| 19 | NewEdge Advisors, LLC | 0 | $0 | — | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in ACXP — a direct measure of their conviction.
Filings activity in ACXP during Q2 2026, grouped by how each filer changed its position.
Institutions that opened a new ACXP position in Q2 2026
Institutions that fully closed their ACXP position in Q2 2026
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 19 | 9.5% | 2.78% | 3.07 pp | $0M | 69% |
| Q1 2026 | 21 | +17% | 5.85% | 0.58 pp | $1M | +74% |
| Q4 2025 | 18 | +13% | 6.43% | +4.96 pp | $0M | +40% |
| Q3 2025 | 16 | 52% | 1.47% | 1.34 pp | $0M | 80% |
| Q2 2025 | 33 | +32% | 2.81% | 1.21 pp | $1M | 8.2% |
| Q1 2025 | 25 | 3.8% | 4.02% | +2.41 pp | $1M | +20% |
| Q4 2024 | 26 | +18% | 1.61% | +0.18 pp | $1M | 52% |
| Q3 2024 | 22 | — | 1.43% | — | $2M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying ACXP stock.
Based on Q2 2026 13F filings, institutional ownership of Acurx Pharmaceuticals, Inc. stands at 2.8%, held across 19 reporting institutions.
VANGUARD CAPITAL MANAGEMENT LLC is the largest reported institutional holder of ACXP, with approximately 31,099 shares worth $0.00B as of Q2 2026.
Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of ACXP, including JANE STREET GROUP, LLC.
Our composite Smart Money Score for ACXP is 30 out of 100 (Bearish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
2 institutions opened new positions in ACXP during Q2 2026, while 4 fully exited. 1 added to existing positions and 16 trimmed.
ACXP institutional ownership fell by 3.07 percentage points quarter-over-quarter, with a net change of -2 holders.
The top 10 institutions account for 99.4% of all reported 13F value in ACXP, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Acurx Pharmaceuticals, Inc. (ACXP) Institutional Ownership